Nicolas Soldermann
Overview
Explore the profile of Nicolas Soldermann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
303
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chapeau E, Sansregret L, Galli G, Chene P, Wartmann M, Mourikis T, et al.
Nat Cancer
. 2024 Jun;
5(7):1130.
PMID: 38886525
No abstract available.
2.
Chapeau E, Sansregret L, Galli G, Chene P, Wartmann M, Mourikis T, et al.
Nat Cancer
. 2024 Apr;
5(7):1102-1120.
PMID: 38565920
The YAP-TEAD protein-protein interaction mediates YAP oncogenic functions downstream of the Hippo pathway. To date, available YAP-TEAD pharmacologic agents bind into the lipid pocket of TEAD, targeting the interaction indirectly...
3.
Sellner H, Chapeau E, Furet P, Voegtle M, Salem B, Le Douget M, et al.
ChemMedChem
. 2023 Mar;
18(11):e202300051.
PMID: 36988034
The inhibition of the YAP-TEAD protein-protein interaction constitutes a promising therapeutic approach for the treatment of cancers linked to the dysregulation of the Hippo signaling pathway. The identification of a...
4.
Furet P, Bordas V, Le Douget M, Salem B, Mesrouze Y, Imbach-Weese P, et al.
ChemMedChem
. 2022 Aug;
17(19):e202200303.
PMID: 35950546
Inhibition of the YAP-TEAD protein-protein interaction is an attractive therapeutic concept under intense investigation with the objective to treat cancers associated with a dysregulation of the Hippo pathway. However, owing...
5.
Rao V, Webster S, Dalm V, Sediva A, van Hagen P, Holland S, et al.
Blood
. 2017 Oct;
130(21):2307-2316.
PMID: 28972011
Pathogenic gain-of-function variants in the genes encoding phosphoinositide 3-kinase δ (PI3Kδ) lead to accumulation of transitional B cells and senescent T cells, lymphadenopathy, and immune deficiency (activated PI3Kδ syndrome [APDS])....
6.
Hoegenauer K, Soldermann N, Zecri F, Strang R, Graveleau N, Wolf R, et al.
ACS Med Chem Lett
. 2017 Sep;
8(9):975-980.
PMID: 28947947
The predominant expression of phosphoinositide 3-kinase δ (PI3Kδ) in leukocytes and its critical role in B and T cell functions led to the hypothesis that selective inhibitors of this isoform...
7.
Hoegenauer K, Soldermann N, Hebach C, Hollingworth G, Lewis I, von Matt A, et al.
Bioorg Med Chem Lett
. 2016 Nov;
26(23):5657-5662.
PMID: 27816514
In the recent years, PI3Kδ has emerged as a promising target for the treatment of B- and T-cell mediated inflammatory diseases. We present a cellular assay activity analysis for our...
8.
Hoegenauer K, Soldermann N, Stauffer F, Furet P, Graveleau N, Smith A, et al.
ACS Med Chem Lett
. 2016 Aug;
7(8):762-7.
PMID: 27563400
Inhibition of the lipid kinase PI3Kδ is a promising principle to treat B and T cell driven inflammatory diseases. Using a scaffold deconstruction-reconstruction strategy, we identified 4-aryl quinazolines that were...
9.
Shaw D, Hollingworth G, Soldermann N, Sprague E, Schuler W, Vangrevelinghe E, et al.
Bioorg Med Chem Lett
. 2014 Sep;
24(20):4812-7.
PMID: 25248678
A novel class of selective inhibitors of ROCK1 and ROCK2 has been identified by structural based drug design. PK/PD experiments using a set of highly selective Rho kinase inhibitors suggest...
10.
Orain D, Ofner S, Koller M, Carcache D, Froestl W, Allgeier H, et al.
Bioorg Med Chem Lett
. 2011 Dec;
22(2):996-9.
PMID: 22197388
A new set of quinazolinedione sulfonamide derivatives as competitive AMPA receptor antagonist with improved properties compared to 1 is disclosed. By modulating physico-chemical properties, compound 29 was identified with a...